Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally ...

Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

Patients with EGFR- and MET-altered NSCLC benefitted from treatment with the drug combo after progressing on Tagrisso alone.

Intensive chemotherapy combined with second- or third-generation tyrosine kinase inhibitors improves survival in patients ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...

BeiGene has seven presentations at IWWM 2024, and Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene, will give the opening ceremony keynote, “Innovating for Impact: How ...

Incyte Corp. has identified tyrosine-protein kinase JAK2 (V617F mutant) inhibitors reported to be useful for the treatment of cancer, hypereosinophilic syndrome, systemic mastocytosis and essential ...

Exelixis (EXEL) stock surged 7.3% after winning a patent battle against generic drug maker MSN Laboratories over Cabometyx.

Wells Fargo analyst Derek Archila has maintained their bullish stance on NRIX stock, giving a Buy rating yesterday. Derek Archila has given ...

Researchers from Nitrase Therapeutics Inc. recently presented preclinical findings on NTX-101, a murine chimeric antibody designed to specifically bind to nitrated tyrosine on α-synuclein (α-Syn). It ...

There are no approved therapies to tackle c-Met protein overexpression, AbbVie said in a press release. C-Met is a receptor ...